Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1956 1
1959 2
1960 1
1961 2
1962 5
1963 3
1964 2
1965 2
1966 2
1967 1
1968 1
1969 2
1970 3
1971 1
1972 1
1973 1
1974 5
1975 6
1976 1
1977 15
1978 7
1979 6
1980 6
1981 5
1982 9
1983 10
1984 12
1985 14
1986 15
1987 20
1988 26
1989 18
1990 22
1991 32
1992 26
1993 37
1994 27
1995 35
1996 40
1997 37
1998 40
1999 47
2000 44
2001 44
2002 54
2003 49
2004 59
2005 70
2006 56
2007 64
2008 51
2009 79
2010 115
2011 120
2012 124
2013 151
2014 148
2015 150
2016 157
2017 167
2018 155
2019 143
2020 146
2021 195
2022 182
2023 178
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

2,993 results

Results by year

Filters applied: . Clear all
Page 1
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Van Cutsem E, Bang YJ, De Vita F, Landers G, Yen CJ, Chau I, Elme A, Lee J, Özgüroglu M, Catenacci D, Yoon HH, Chen E, Adelberg D, Shih CS, Shah S, Bhagia P, Wainberg ZA. Chao J, et al. Among authors: shih cs. JAMA Oncol. 2021 Jun 1;7(6):895-902. doi: 10.1001/jamaoncol.2021.0275. JAMA Oncol. 2021. PMID: 33792646 Free PMC article.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yanez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin SK, Van Cutsem E, Tabernero J, Li K, Shih CS, Bhagia P, Rha SY; KEYNOTE-811 Investigators. Janjigian YY, et al. Among authors: shih cs. Lancet. 2023 Dec 9;402(10418):2197-2208. doi: 10.1016/S0140-6736(23)02033-0. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871604 Clinical Trial.
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR; Neurofibromatosis Clinical Trials Consortium; Blakeley JO, Clapp DW. Fisher MJ, et al. Among authors: shih cs. Nat Med. 2021 Jan;27(1):165-173. doi: 10.1038/s41591-020-01193-6. Epub 2021 Jan 13. Nat Med. 2021. PMID: 33442015 Free PMC article. Clinical Trial.
Pathology in Practice.
Chang YS, Chiang C, Shih CH, Lin LS. Chang YS, et al. Among authors: shih ch. J Am Vet Med Assoc. 2022 May 18;259(S2):1-3. doi: 10.2460/javma.21.05.0231. J Am Vet Med Assoc. 2022. PMID: 35576180 Free article.
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.
Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. Shah MA, et al. Among authors: shih cs. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. Future Oncol. 2021. PMID: 33533655 Free PMC article. Clinical Trial.
Wireless, closed-loop, smart bandage with integrated sensors and stimulators for advanced wound care and accelerated healing.
Jiang Y, Trotsyuk AA, Niu S, Henn D, Chen K, Shih CC, Larson MR, Mermin-Bunnell AM, Mittal S, Lai JC, Saberi A, Beard E, Jing S, Zhong D, Steele SR, Sun K, Jain T, Zhao E, Neimeth CR, Viana WG, Tang J, Sivaraj D, Padmanabhan J, Rodrigues M, Perrault DP, Chattopadhyay A, Maan ZN, Leeolou MC, Bonham CA, Kwon SH, Kussie HC, Fischer KS, Gurusankar G, Liang K, Zhang K, Nag R, Snyder MP, Januszyk M, Gurtner GC, Bao Z. Jiang Y, et al. Among authors: shih cc. Nat Biotechnol. 2023 May;41(5):652-662. doi: 10.1038/s41587-022-01528-3. Epub 2022 Nov 24. Nat Biotechnol. 2023. PMID: 36424488
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Fuchs CS, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, Fornaro L, Olesinski T, Caglevic C, Chung HC, Muro K, Van Cutsem E, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Bhagia P, Wang A, Shih CS, Shitara K. Fuchs CS, et al. Among authors: shih cs. Gastric Cancer. 2022 Jan;25(1):197-206. doi: 10.1007/s10120-021-01227-z. Epub 2021 Sep 1. Gastric Cancer. 2022. PMID: 34468869 Free PMC article. Clinical Trial.
2,993 results